BioWorld

July 3, 2002

ARYx Raises $25M To Develop Drugs Using Retrometabolics

ARYx Therapeutics Inc. raised $25 million in a Series C round of financing - it's largest to date - and will use the funds to continue its progress as the Volvo of the drug industry. (BioWorld Today) Read More

Centocor's Remicade Approved For Another Crohn's Indication

Plumbing Molecular Depths Of Asthma's Symptoms Turns Up 2 Culprits: Interleukin-13, STAT6

Medisyn's 'Forward Engineering' Technology Used In Cancer Effort

Holiday Notice

Other News To Note

U.S. Patent Disclosures

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for Jan 26, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 27, 2026.

DNA mutations or genetic disorder concept art

Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease

BioWorld Science

Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...

Muted and missing M&As: JPM deals absent in 2026

BioWorld

For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...

Brain-derived tau in blood predicts stroke severity and outcome

BioWorld Science

Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...